Francois Nader - 30 Apr 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
30 Apr 2025
Transactions value $
$0
Form type
4
Filing time
01 May 2025, 16:33:15 UTC
Previous filing
07 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +6.38K $0.00 6.38K 30 Apr 2025 Common Stock 6.38K $28.54 Direct F1
transaction MRNA Restricted Stock Units Award $0 +12.2K $0.00 12.2K 30 Apr 2025 Common Stock 12.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.